Hedgehog pathway inhibitor

This page covers all Hedgehog pathway inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Smoothened (transmembrane protein), Smoothened homolog, Smoothened (SMO).

Targets

Smoothened (transmembrane protein) · Smoothened homolog · Smoothened (SMO) · Smoothened · Sonic hedgehog receptor

Marketed (7)

• Daurismo · Pfizer · Oncology · 150
  Glasdegib inhibits Smoothened, a transmembrane protein in the Hedgehog signaling pathway.
• Daurismo · Pfizer · Oncology · 150
  Daurismo works by blocking the Smoothened homolog, a protein involved in the Hedgehog signaling pathway, which is often dysregulated in cancer cells.
• Treatment with vismodegib · University Hospital, Bordeaux · Oncology
  Vismodegib inhibits the Hedgehog signaling pathway by blocking Smoothened, a key transmembrane protein required for pathway activation.
• ERIVEDGE · University Hospital, Lille · Oncology
  Erivedge (vismodegib) inhibits the Hedgehog signaling pathway by blocking Smoothened, a key transmembrane protein required for pathway activation.
• Sonidegib Phosphate Capsules · Jemincare · Oncology
  Sonidegib is a Hedgehog pathway inhibitor that blocks Smoothened (SMO) signaling to suppress aberrant cell proliferation driven by Hedgehog pathway activation.
• Erivedge · Roche · Oncology
  Vismodegib inhibits the Hedgehog pathway by binding to and blocking Smoothened, a key protein in the pathway.
• GLASDEGIB

Phase 2 pipeline (1)

• AltSonflex1-2-3 · GlaxoSmithKline · Oncology
  AltSonflex1-2-3 is a small molecule that modulates the sonic hedgehog signaling pathway.

Patent intelligence

• hedgehog pathway inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates